{"id":"W4226457448","doi":"10.1182/blood-2021-154490","title":"Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"CD47; Medicine; Lymphoma; Immune system; Immunology; Internal medicine; Oncology; Pharmacology; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004803945,0.001222881,0.001880194,0.0005246463,0.0004929401,0.001634803,0.001112845,0.001651761,0.003937787],"category_scores_gemma":[0.002008563,0.0005462031,0.00147005,0.0006062603,0.0005568108,0.001024067,0.0004585587,0.003498719,0.001052426],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00118166,"about_ca_system_score_gemma":0.002040552,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000977424,"about_ca_topic_score_gemma":0.003343258,"domain_scores_codex":[0.9983338,0.0009110912,0.0001038095,0.0001296702,0.000281473,0.0002402981],"domain_scores_gemma":[0.9985567,0.000257459,0.0003540649,0.0001336084,0.0002132541,0.0004850805],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2127358,0.05485089,0.01962927,0.002024824,0.002353584,0.0006448208,0.0008866388,0.008891957,0.1474205,0.001125856,0.04260426,0.5068316],"study_design_scores_gemma":[0.2356788,0.5935431,0.04343327,0.0003805963,0.001967073,0.00124329,0.0002691031,0.003329846,0.02983754,0.001246975,0.08896615,0.0001042986],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9417382,0.01706352,0.004221046,0.00557544,0.0005437545,0.009551303,0.008144975,0.0008768731,0.01228489],"genre_scores_gemma":[0.9301993,0.01145396,0.01251132,0.008684619,0.0006049283,0.01150348,0.01562706,0.0002667184,0.009148665],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004803945,"threshold_uncertainty_score":0.02540594,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01360797812006943,"score_gpt":0.2381929705666236,"score_spread":0.2245849924465541,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}